Linked Life Data

7332192

Source:http://linkedlifedata.com/resource/pubmed/id/7332192

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
1982-4-20
pubmed:abstractText
This study of the Rennes anti-cancer Center reports the results of a clinical and isotope scan study of Dihydroergotamine-Sandoz in the treatment of post-radiotherapy hyposialorrhoea. Dihydroergotamine was used at an initial dose of 100 drops 3 times per day for two weeks, then 60 drops 3 times per day. Treatment must be continued for several months. The results of such treatment given to 11 patients in comparison with a "control" group of 19 patients were evaluated objectively using isotope studies of salivary function. It was found, in addition, that the interruption of treatment might be associated with a relapse of symptoms, reversible when the drug was restarted. Finally, and in the light of the results of this study, it would appear to be logical to treat patients immediately following the end of radiotherapy without awaiting the first symptoms of hyposialorrhoea.
pubmed:language
fre
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0003-438X
pubmed:author
pubmed:issnType
Print
pubmed:volume
98
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
309-15
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1981
pubmed:articleTitle
[The value of the treatment of post-radiotherapy hyposialorrhoea by dihydroergotamine (author's transl)].
pubmed:publicationType
Journal Article, English Abstract, Case Reports